Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Vepdegestrant in Healthy Participants
NCT06911788Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2025
- Primary completion
- May 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in hormone receptor-positive/HER2-negative breast cancer, sponsored by Pfizer. Primary endpoint: Dose-normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time. Started Apr 2025; status: completed.
02
Drugs
vepdegestrant
03
Conditions
hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on NCT06911788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911788.